Bill > S3188

This bill establishes a National Biopharmaceutical Manufacturing Center of Excellence through the National Institute of Standards and Technology to advance biotechnology capabilities in the United States. The center would be created through a competitive grant process, targeting an eligible entity like a public-private partnership or academic institution to develop innovative biopharmaceutical manufacturing technologies. Key objectives include advancing biomanufacturing science, supporting good manufacturing practices, developing workforce training programs, and strengthening national security by reducing dependency on foreign supply chains. The center will focus on improving manufacturing technologies for products critical to national, health, and economic security, engage with various stakeholders including universities, pharmaceutical manufacturers, government agencies, and non-profit organizations, and work to standardize and improve biopharmaceutical production processes. The bill authorizes $120 million in funding for fiscal year 2026 and requires the director to submit annual reports to Congress detailing the center's progress, activities, and findings. The legislation also includes comprehensive definitions of key terms like biotechnology, biomanufacturing, and biopharmaceuticals, emphasizing the potential of biological engineering to transform industries ranging from medicine to agriculture.

Transportation and Infrastructure

https://www.congress.gov/bill/119th-congress/senate-bill/3188/all-info